SMARCE1

SMARCE1 Full Name

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1

SMARCE1 Introduction

SMARCE1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1), also known as BAF57, is a core component of the ATP-dependent SWI/SNF (BAF) chromatin remodeling complex that regulates how DNA is packaged and accessed within the nucleus. For researchers studying epigenetic regulation, cancer biology, or developmental disorders, understanding SMARCE1 is critical because alterations in chromatin remodeling machinery can disrupt normal gene expression programs and contribute to disease progression. SMARCE1 contains an HMG (high mobility group) DNA-binding domain that enables the SWI/SNF complex to interact with specific genomic regions, allowing precise control of nucleosome positioning, transcription factor accessibility, and chromatin architecture. As an essential regulatory subunit of cBAF and PBAF complexes, SMARCE1 supports coordinated chromatin remodeling activities required for transcriptional regulation, DNA replication, DNA repair, and genome stability.

At the molecular level, SMARCE1 functions as a structural and regulatory organizer within the SWI/SNF complex, helping maintain complex integrity and directing remodeling activity toward appropriate genomic sites. By controlling nucleosome dynamics, SMARCE1 influences key cellular processes including cell cycle progression, stem cell maintenance, lineage differentiation, immune regulation, and tissue development. Recent mechanistic studies have shown that SMARCE1 deficiency destabilizes SWI/SNF complexes, reduces nucleosome remodeling capacity, and alters chromatin accessibility patterns, leading to abnormal transcriptional states. In embryonic stem cells, loss of SMARCE1 impairs proper chromatin maturation and differentiation by disrupting nucleosome stability and preventing establishment of lineage-specific gene expression programs. These findings highlight SMARCE1 as an important epigenetic regulator that connects chromatin organization with cellular identity and developmental control.

Dysfunction of SMARCE1 has been strongly associated with human disease, particularly cancer and developmental abnormalities. Germline mutations in SMARCE1 are a well-established genetic driver of clear cell meningioma, a rare but aggressive subtype of central nervous system tumor, where SMARCE1 loss disrupts SWI/SNF complex stability and creates unique molecular vulnerabilities that may be therapeutically targeted. Beyond meningioma, abnormal SMARCE1 activity has been implicated in broader tumor biology due to its role in maintaining genome integrity and regulating tumor-suppressive chromatin states. Emerging research also suggests that SMARCE1 contributes to embryonic development, cardiac cell proliferation, and differentiation processes, indicating potential relevance in congenital disorders and regenerative medicine. As precision oncology and epigenetic therapies continue to advance, SMARCE1 represents an important biomarker and therapeutic research target for understanding chromatin remodeling defects and developing strategies against SWI/SNF-driven diseases.

Alternate Names for SMARCE1

SMARCE1; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1; BAF57; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1; BRG1-associated factor 57; chromatin remodeling complex BRG1-associated factor 57; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin e1

• 1.Li Y, et al.; Biological functions of BAF57, its role in disease pathogenesis, and treatment: From molecular mechanisms to clinical translation. Prog Biophys Mol Biol. 2026, 201:139-151.
  2.St Pierre R, et al.; SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma. Nat Genet. 2022, 54(6):861-873.